文献速递结核与非结核分枝杆菌艾滋病与性传播感染细菌感染、耐药与抗菌药物

多替拉韦与每周一次异烟肼和利福喷丁药物相互作用研究中细胞因子介导的全身性药物不良反应

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
PubMed 文献 · Clin Infect Dis · 2018-01-01

这项单中心、开放标签、固定序列药物相互作用研究在健康志愿者中评估多替拉韦与每周一次异烟肼和利福喷丁联用的药代动力学。4名受试者中2人在第三次异烟肼-利福喷丁给药后出现流感样综合征和转氨酶升高,研究因此终止,干扰素-γ、CXCL10、C反应蛋白等细胞因子显著升高与症状在时间上相关。作者认为联用导致由内源性细胞因子释放介导的意外严重毒性,需进一步研究联用的安全性和有效性。

要点

  • 4名受试者中2人在第三次异烟肼-利福喷丁给药后出现流感样综合征和转氨酶升高,研究终止。
  • 干扰素-γ、CXCL10、C反应蛋白等细胞因子显著升高与症状在时间上相关。
  • 第14天多替拉韦AUC降低46%(90%CI 27-110%;P=.13),作者结论为需进一步研究联用的安全性和有效性。

核心结论

  • 多替拉韦与每周一次异烟肼-利福喷丁联用导致由内源性细胞因子释放介导的意外严重毒性。
  • 作者认为需进一步研究这些药物联用的安全性和有效性。

研究设计与样本

  • 单中心、开放标签、固定序列药物相互作用研究,在健康志愿者中进行。
  • 受试者先单独口服多替拉韦50 mg每日一次(第1-4天),随后联用每周一次异烟肼900 mg、利福喷丁900 mg和吡哆醇50 mg(第5-19天)。
  • 第4、14、19天测定多替拉韦浓度,第19天测定利福喷丁、25-去乙酰利福喷丁和异烟肼浓度,并在选定时间点检测细胞因子及抗异烟肼和利福喷丁抗体。

主要发现

  • 4名受试者中2人在第三次异烟肼-利福喷丁给药后出现流感样综合征和转氨酶升高,研究因此终止。
  • 干扰素-γ、CXCL10、C反应蛋白及其他细胞因子水平显著升高与症状在时间上相关。
  • 抗药物抗体检出率低。
  • 第14天多替拉韦AUC降低46%(90%置信区间27-110%;P=.13)。
  • 第19天利福喷丁和25-去乙酰利福喷丁水平与参考数据相当,而发生毒性受试者的异烟肼AUC约高67%-92%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因4名受试者中2人出现流感样综合征和转氨酶升高而终止。
  • 作者结论指出需进一步研究这些药物联用的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection. This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and dolutegravir, a first-line antiretroviral medication. METHODS: This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers. Subjects received oral dolutegravir 50 mg once daily alone (days 1-4) and concomitantly with once-weekly isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19). Dolutegravir concentrations were measured on days 4, 14, and 19, and rifapentine, 25-desacetyl-rifapentine, and isoniazid concentrations were measured on day 19. Cytokines and antidrug antibodies to isoniazid and rifapentine were examined at select time points. RESULTS: The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third isoniazid-rifapentine dose. Markedly elevated levels of interferon-γ, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms. Antidrug antibodies were infrequently detected. Dolutegravir area under the curve (AUC) was decreased by 46% (90% confidence interval, 27-110%; P = .13) on day 14. Rifapentine and 25-desacetyl rifapentine levels on day 19 were comparable to reference data, whereas isoniazid AUCs were approximately 67%-92% higher in the subjects who developed toxicities. CONCLUSIONS: The combined use of dolutegravir with once-weekly isoniazid-rifapentine resulted in unexpected and serious toxicities that were mediated by endogenous cytokine release. Additional investigations are necessary to examine the safety and efficacy of coadministering these medications. CLINICAL TRIALS REGISTRATION: NCT02771249.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brooks KM, George JM, Pau AK, et al. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis. 2018. PMID: 29415190. doi:10.1093/cid/ciy082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。